SCHEMBL26010069

SCHEMBL26010069

CN[C@H](C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)N1CCCCC1)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.41
CTSL P07711 2/20 0.41
CTSB P07858 1/20 0.41
TSHR P16473 1/20 0.38
CYP2D6 P10635 1/20 0.37
KMT2A Q03164 3/20 0.37
PREP P48147 1/20 0.34
ITGB3 P05106 3/20 0.33
ITGA2B P08514 3/20 0.33
MEN1 O00255 2/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP8 P22894 1/20 0.33
CTSS P25774 1/20 0.33
CALCRL Q16602 1/20 0.33
RRM1 P23921 2/20 0.33
RRM2 P31350 2/20 0.33
RRM2B Q7LG56 2/20 0.33
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24217733 0.84 MMP2 (0.36) KMT2AMEN1MMP1MMP2MMP8
SCHEMBL24822362 0.84 HPGD (0.38) CTSKCTSLCTSBCYP2D6KMT2A
SCHEMBL23879097 0.84 HPGD (0.38) CTSKCTSLCTSBCYP2D6KMT2A
SCHEMBL7298353 0.81 CYP2D6 (0.46) CTSKCTSLCTSBTSHRCYP2D6
SCHEMBL29973257 0.80 CYP2D6 (0.43) CTSKCTSLCTSBCYP2D6KMT2A
SCHEMBL15653266 0.80 CYP2D6 (0.43) CTSKCYP2D6KMT2AMEN1MMP1
SCHEMBL23893541 0.80 P2RY12 (0.36) CTSKCTSLCTSBCYP2D6ITGB3
SCHEMBL14580885 0.79 CTSK (0.38) CTSKCTSLCTSBCYP2D6KMT2A
SCHEMBL13030795 0.79 CTSK (0.35) CTSKCTSLCTSBCYP2D6KMT2A
SCHEMBL26013230 0.77 HPGD (0.38) CTSKCTSLCTSBCYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303619-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-09-28 US disclosed
US-11732002-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11732002-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound VIP, PEPD, MLN CTSK 423/4885CTSL 172/4885CTSB 348/4885
US-20230303619-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND VIP, PEPD, MLN CTSK 423/4885CTSL 172/4885CTSB 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.